REGN Financials Regeneron Pharmaceuticals

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated 29 h ago Overview →

Growth & profitability

Revenue has grown 11.0% per year over the past 5 years.
Net income has grown slower than revenue (5.1% vs 11.0% per year).
Operating margin has contracted, at 24.9% in the latest year.
Free cash flow has grown 15.3% per year over the past 5 years.

Financial health

The company holds more cash ($3.1B) than total debt ($2.0B).
Total debt has grown slower than revenue (0.1% vs 11.0% per year).
Operating income covered interest expense 82× in the latest year.
Total debt is 0.5× EBITDA.

Shareholder returns

Dividends have been paid for 1 consecutive year, consuming 8.2% of earnings and 9.1% of free cash flow.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
2025	$14.3B	$4.5B	0.0%	24.9%	$4.1B	$2.0B	$3.1B
2024	$14.2B	$4.4B	0.0%	28.1%	$3.7B	$2.0B	$2.5B
2023	$13.1B	$4.0B	0.0%	30.9%	$3.9B	$2.0B	$2.7B
2022	$12.2B	$4.3B	0.0%	38.9%	$4.4B	$2.0B	$3.1B
2021	$16.1B	$8.1B	0.0%	55.7%	$6.5B	$2.0B	$2.9B
2020	$8.5B	$3.5B	0.0%	42.1%	$2.0B	$2.0B	$2.2B
2019	$6.6B	$2.1B	93.9%	33.7%	$2.0B	$0	$1.6B
2018	$5.1B	$2.4B	95.4%	49.3%	$1.8B	—	$1.5B
2017	$5.9B	$1.2B	0.0%	35.4%	$1.0B	—	$813M
2016	$4.9B	$896M	0.0%	27.4%	$974M	—	$535M
2015	—	$636M	—	—	$653M	—	$809M
2014	—	$338M	—	—	$419M	—	$649M
2013	—	$414M	—	—	$432M	—	$536M
2012	—	$750M	—	—	-$124M	—	$230M
2011	—	-$222M	—	—	-$199M	—	$484M

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
Mar '26	$3.6B	$727M	0.0%	17.8%	$848M	$2.0B	$3.0B
Dec '25	$3.9B	$845M	0.0%	22.7%	$922M	$2.0B	$3.1B
Sep '25	$3.8B	$1.5B	0.0%	27.3%	$1.4B	$2.0B	$2.5B
Jun '25	$3.7B	$1.4B	0.0%	29.4%	$925M	$2.0B	$2.0B
Mar '25	$3.0B	$809M	0.0%	19.5%	$816M	$2.0B	$3.1B
Dec '24	$3.8B	$918M	0.0%	26.1%	$1.1B	$2.0B	$2.5B
Sep '24	$3.7B	$1.3B	0.0%	31.7%	$1.0B	$2.0B	$2.0B
Jun '24	$3.5B	$1.4B	0.0%	30.2%	$174M	$2.0B	$1.9B
Mar '24	$3.1B	$722M	0.0%	23.9%	$1.4B	$2.0B	$2.6B
Dec '23	$3.4B	$1.2B	0.0%	28.3%	$838M	$2.0B	$2.7B
Sep '23	$3.4B	$1.0B	0.0%	33.0%	$938M	$2.0B	$2.2B
Jun '23	$3.2B	$968M	0.0%	32.2%	$909M	$2.0B	$1.9B
Mar '23	$3.2B	$818M	0.0%	29.9%	$1.2B	$2.0B	$3.9B
Dec '22	$3.4B	$1.2B	0.0%	33.6%	$1.6B	$2.0B	$3.1B
Sep '22	$2.9B	$1.3B	0.0%	41.7%	$486M	$2.0B	$3.5B
Jun '22	$2.9B	$852M	0.0%	38.8%	$411M	$2.0B	$3.4B
Mar '22	$3.0B	$974M	0.0%	42.4%	$2.0B	$2.0B	$3.3B
Dec '21	$5.0B	$2.2B	0.0%	53.3%	$2.2B	$2.0B	$2.9B
Sep '21	$3.5B	$1.6B	0.0%	53.5%	$3.3B	$2.0B	$3.4B
Jun '21	$5.1B	$3.1B	0.0%	65.1%	$478M	$2.0B	$2.1B

Valuation over time

How the market has priced REGN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has fallen from 19.7× (Mar '23) to 14.3× (Jun '26).
The price-to-sales ratio has fallen from 7.0× (Mar '23) to 4.5× (Jun '26).
The dividend yield has risen from 0.5% (Dec '25) to 0.6% (Jun '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is REGN growing its revenue and profit?

Over the past 5 years, Regeneron Pharmaceuticals's revenue has grown 11.0% per year, and net income grown 5.1% per year. These are computed facts, not advice.

How much debt does REGN have?

As of FY2025, Regeneron Pharmaceuticals reported $2.0B of total debt against $3.1B of cash; operating income covered interest expense 82×.

What is REGN's profit margin?

In FY2025, gross margin was —, operating margin 24.9%, and net margin 31.4%.

What is REGN's P/E ratio?

As of Jun '26, Regeneron Pharmaceuticals traded at a price-to-earnings ratio of about 14.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.